Adaptive Biotechnologies Corporation
Adaptive Biotechnologies is a pioneer and leader in the field of immunosequencing. Adaptive leverages its technology platform to power innovative clinical diagnostics, enable groundbreaking research, and drive therapeutic development to improve patient care. Adaptive’s lead clinical diagnostic, the clonoSEQ® Assay, provides standardized, sensitive, and specific assessment of measurable residual disease (MRD) in patients with lymphoid cancers like acute lymphoblastic leukemia and myeloma.